The Bambusa IPO was priced at $16 per share on October 30, 2026, with the clinical-stage biotechnology company expecting to raise $168,888,880 before underwriting costs and other expenses.

Key Takeaways

  • Bambusa is offering 10,555,555 shares and expects trading under the symbol BBTX to begin October 30.
  • The offering is expected to close November 2, subject to customary conditions.

Bambusa IPO terms and listing

Bambusa Therapeutics increased the size of its offering from the 9,375,000 shares proposed in its October 26 preliminary prospectus. That filing anticipated a price of $15 to $17 per share; the final $16 price is the midpoint of that range.

The company is selling all the shares in the offering and has granted underwriters a 30-day option to purchase up to 1,583,333 additional shares at the IPO price, less underwriting discounts and commissions. The expected gross proceeds exclude any proceeds from that option.

The shares are expected to begin trading on the Nasdaq Global Select Market under BBTX. The registration statements became effective October 29. BofA Securities, Evercore ISI, UBS Investment Bank and Cantor are the joint book-running managers.

Company and drug pipeline

Boston-based Bambusa is developing long-acting bispecific antibodies for immunology and inflammation. Its BBT001 candidate is in clinical development for atopic dermatitis and other inflammatory skin diseases, while BBT002 is in clinical development for Type 2 inflammatory disorders.

The company’s preliminary IPO prospectus describes its clinical development programs and the risks associated with investing in its shares. Bambusa also has two preclinical programs focused on gastroenterology and autoantibody-driven autoimmune diseases.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.